Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections-A Systematic Review and Meta-Analysis.
Acute Disease
Angiotensin-Converting Enzyme 2
/ metabolism
Angiotensin-Converting Enzyme Inhibitors
Arrhythmias, Cardiac
/ etiology
COVID-19
/ complications
Down-Regulation
Heart Failure
/ etiology
Humans
Influenza A virus
/ metabolism
Influenza B virus
/ metabolism
Influenza, Human
/ complications
Myocardial Ischemia
/ etiology
SARS-CoV-2
/ metabolism
Journal
Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
pubmed:
20
4
2021
medline:
31
8
2021
entrez:
19
4
2021
Statut:
ppublish
Résumé
Severe acute respiratory syndrome-related coronavirus-2 binds and inhibits angiotensin-converting enzyme-2. The frequency of acute cardiac injury in patients with coronavirus disease 2019 is unknown. The objective was to compare the rates of cardiac injury by angiotensin-converting enzyme-2-binding viruses from viruses that do not bind to angiotensin-converting enzyme-2. We performed a systematic review of coronavirus disease 2019 literature on PubMed and EMBASE. We included studies with ten or more hospitalized adults with confirmed coronavirus disease 2019 or other viral pathogens that described the occurrence of acute cardiac injury. This was defined by the original publication authors or by: 1) myocardial ischemia, 2) new cardiac arrhythmia on echocardiogram, or 3) new or worsening heart failure on echocardiogram. We compared the rates of cardiac injury among patients with respiratory infections with viruses that down-regulate angiotensin-converting enzyme-2, including H1N1, H5N1, H7N9, and severe acute respiratory syndrome-related coronavirus-1, to those with respiratory infections from other influenza viruses that do not bind angiotensin-converting enzyme-2, including Influenza H3N2 and influenza B. Of 57 studies including 34,072 patients, acute cardiac injury occurred in 50% (95% CI, 44-57%) of critically ill patients with coronavirus disease 2019. The overall risk of acute cardiac injury was 21% (95% CI, 18-26%) among hospitalized patients with coronavirus disease 2019. In comparison, 37% (95% CI, 26-49%) of critically ill patients with other respiratory viruses that bind angiotensin-converting enzyme-2 (p = 0.061) and 12% (95% CI, 7-22%) of critically ill patients with other respiratory viruses that do not bind angiotensin-converting enzyme-2 (p < 0.001) experienced a cardiac injury. Acute cardiac injury may be associated with whether the virus binds angiotensin-converting enzyme-2. Acute cardiac injury occurs in half of critically ill coronavirus disease 2019 patients, but only 12% of patients infected by viruses that do not bind to angiotensin-converting enzyme-2.
Identifiants
pubmed: 33870918
doi: 10.1097/CCM.0000000000005026
pii: 00003246-202109000-00017
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Comparative Study
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1558-1566Informations de copyright
Copyright © 2021 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Déclaration de conflit d'intérêts
Dr. Cheng’s institution received funding from Canadian Institutes of Health Research (CIHR), and he disclosed being on the scientific advisory board of GEN1E LifeSciences. Dr. Lee received funding from Fonds de Recherche du Québec Santé. Dr. Brodie’s institution received funding from ALung Technologies, and he received funding from Baxter, Xenios, BREETHE, and Hemovent. Dr. Slutsky received funding from Apeiron Biologics (which is investigating recombinant angiotensin-converting enzyme 2 as a treatment for coronavirus disease 2019 [COVID-19]). Dr. Marshall received funding from AM Pharma and AKPA Pharma. Dr. Bogoch received funding from BlueDot. Dr. Russell received funding from Asahi Kesai Pharmaceuticals of America, SIB Therapeutics, Ferring Pharmaceuticals, and previously received funding for consulting for La Jolla Pharmaceuticals and PAR Pharma. Dr. Russell reports patents owned by the University of British Columbia (UBC) that are related to the use of PCSK9 inhibitor(s) in sepsis and related to the use of vasopressin in septic shock, and he is an inventor on these patents. Dr. Russell was a founder, Director, and shareholder in Cyon Therapeutics Inc. and is a shareholder in Molecular You Corp. Dr. Russell reports having received an investigator-initiated grant from Grifols (entitled “Is HBP a mechanism of albumin’s efficacy in human septic shock?”) that was provided to and administered by UBC. Dr. Russell received support for article research from the CIHR. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Références
Wrapp D, Wang N, Corbett KS, et al.: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367:1260–1263
Hoffmann M, Kleine-Weber H, Schroeder S, et al.: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181:271–e8280
Chen N, Zhou M, Dong X, et al.: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395:507–513
Huang C, Wang Y, Li X, et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506
Kuba K, Imai Y, Rao S, et al.: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11:875–879
Wang D, Hu B, Hu C, et al.: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323:1061–1069
Huang F, Guo J, Zou Z, et al.: Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun 2014; 5:3595
Yang P, Gu H, Zhao Z, et al.: Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep 2014; 4:7027
Stevens J, Chen LM, Carney PJ, et al.: Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs. J Virol 2010; 84:8287–8299
Shen C, Chen J, Li R, et al.: A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci Transl Med 2017; 9:eaam5752
Velkov T: The specificity of the influenza B virus hemagglutinin receptor binding pocket: What does it bind to? J Mol Recognit 2013; 26:439–449
Wang Q, Tian X, Chen X, et al.: Structural basis for receptor specificity of influenza B virus hemagglutinin. Proc Natl Acad Sci U S A 2007; 104:16874–16879
Schwarzer G, Chemaitelly H, Abu-Raddad LJ, et al.: Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods 2019; 10:476–483
Stijnen T, Hamza TH, Ozdemir P: Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med 2010; 29:3046–3067
Hoy D, Brooks P, Woolf A, et al.: Assessing risk of bias in prevalence studies: Modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012; 65:934–939
Bauchner H, Golub RM, Zylke J: Editorial concern-possible reporting of the same patients with COVID-19 in different reports. JAMA 2020; 323:1256
Liu X, Yang N, Tang J, et al.: Downregulation of angiotensin-converting enzyme 2 by the neuraminidase protein of influenza A (H1N1) virus. Virus Res 2014; 185:64–71
Chen T, Wu D, Chen H, et al.: Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ 2020; 368m1091
Chen L, Li X, Chen M, et al.: The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res 2020; 116:1097–1100
Monteil V, Kwon H, Prado P, et al.: Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020; 181:905–e7913
Fried JA, Ramasubbu K, Bhatt R, et al.: The variety of cardiovascular presentations of COVID-19. Circulation 2020; 141:1930–1936
Klok FA, Kruip MJHA, van der Meer NJM, et al.: Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191:145–147
Zhou F, Yu T, Du R, et al.: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395:1054–1062
Wang J, Xu H, Yang X, et al.: Cardiac complications associated with the influenza viruses A subtype H7N9 or pandemic H1N1 in critically ill patients under intensive care. Braz J Infect Dis 2017; 21:12–18
Nin N, Lorente JA, Soto L, et al.: Acute kidney injury in critically ill patients with 2009 influenza A (H1N1) viral pneumonia: An observational study. Intensive Care Med 2011; 37:768–774
Viasus D, Oteo Revuelta JA, Martínez-Montauti J, et al.: Influenza A(H1N1)pdm09-related pneumonia and other complications. Enferm Infecc Microbiol Clin 2012; 30(Suppl 4):43–48
Kuster SP, Katz KC, Blair J, et al.: When should a diagnosis of influenza be considered in adults requiring intensive care unit admission? Results of population-based active surveillance in Toronto. Crit Care 2011; 15:R182
Chacko B, Peter JV, Pichamuthu K, et al.: Cardiac manifestations in patients with pandemic (H1N1) 2009 virus infection needing intensive care. J Crit Care 2012; 27:106.e101–e106106
Chacko J, Gagan B, Ashok E, et al.: Critically ill patients with 2009 H1N1 infection in an Indian ICU. Indian J Crit Care Med 2010; 14:77–82
Nicolay N, Callaghan MA, Domegan LM, et al.: Epidemiology, clinical characteristics and resource implications of pandemic (H1N1) 2009 in intensive care units in Ireland. Crit Care Resusc 2010; 12:255–261
Bagshaw SM, Sood MM, Long J, et al.; Canadian Critical Care Trials Group H1N1 Collaborative: Acute kidney injury among critically ill patients with pandemic H1N1 influenza A in Canada: Cohort study. BMC Nephrol 2013; 14:123
Brown SM, Pittman J, Miller Iii RR, et al.: Right and left heart failure in severe H1N1 influenza A infection. Eur Respir J 2011; 37:112–118
Erden I, Erden EC, Ozhan H, et al.: Echocardiographic manifestations of pandemic 2009 (H1N1) influenza a virus infection. J Infect 2010; 61:60–65
Fagnoul D, Pasquier P, Bodson L, et al.: Myocardial dysfunction during H1N1 influenza infection. J Crit Care 2013; 28:321–327
Lee N, Chan PK, Lui GC, et al.: Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: How do they differ from those in seasonal influenza? J Infect Dis 2011; 203:1739–1747
Fowler RA, Lapinsky SE, Hallett D, et al.; Toronto SARS Critical Care Group: Critically ill patients with severe acute respiratory syndrome. JAMA 2003; 290:367–373
Gomersall CD, Joynt GM, Lam P, et al.: Short-term outcome of critically ill patients with severe acute respiratory syndrome. Intensive Care Med 2004; 30:381–387
Yu CM, Wong RS, Wu EB, et al.: Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J 2006; 82:140–144
Lew TW, Kwek TK, Tai D, et al.: Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 2003; 290:374–380
Han J, Mou Y, Yan D, et al.: Transient cardiac injury during H7N9 infection. Eur J Clin Invest 2015; 45:117–125
Gao C, Wang Y, Gu X, et al.: Association between cardiac injury and mortality in hospitalized patients infected with avian influenza A (H7N9) virus. Crit Care Med 2020
Ma W, Huang H, Chen J, et al.: Predictors for fatal human infections with avian H7N9 influenza, evidence from four epidemic waves in Jiangsu Province, Eastern China, 2013-2016. Influenza Other Respir Viruses 2017; 11:418–424
Chen X, Yang Z, Lu Y, et al.: Clinical features and factors associated with outcomes of patients infected with a Novel Influenza A (H7N9) virus: A preliminary study. PLoS One 2013; 8:e73362
Zheng S, Zou Q, Wang X, et al.: Factors associated with fatality due to avian influenza A(H7N9) infection in China. Clin Infect Dis 2020; 71:128–132
Harris JE, Shah PJ, Korimilli V, et al.: Frequency of troponin elevations in patients with influenza infection during the 2017–2018 influenza season. IJC Heart & Vasculature 2019; 22:145–147
Abaziou T, Delmas C, Vardon Bounes F, et al.: Outcome of critically ill patients with influenza infection: A retrospective study. Infect Dis (Auckl) 2020; 13:1178633720904081
Pizzini A, Burkert F, Theurl I, et al.: Prognostic impact of high sensitive Troponin T in patients with influenza virus infection: A retrospective analysis. Heart Lung 2020; 49:105–109
Hu CA, Chen CM, Fang YC, et al.; TSIRC (Taiwan Severe Influenza Research Consortium): Using a machine learning approach to predict mortality in critically ill influenza patients: A cross-sectional retrospective multicentre study in Taiwan. BMJ Open 2020; 10:e033898
Naudion P, Lepiller Q, Bouiller K: Risk factors and clinical characteristics of patients with nosocomial influenza A infection. J Med Virol 2020; 92:1047–1052
Zhang Y, Wang Y, Zhao J, et al.; CAP-China Network: Severity and mortality of respiratory syncytial virus vs influenza A infection in hospitalized adults in China. Influenza Other Respir Viruses 2020; 14:483–490
Chow EJ, Rolfes MA, O’Halloran A, et al.: Acute cardiovascular events associated with influenza in hospitalized adults: A cross-sectional study. Ann Intern Med 2020; 173:605–613